Molecular therapeutic targets in rheumatoid arthritis

Sacre, Sandra M, Andreakos, Evangelos, Taylor, Peter, Feldmann, Marc and Foxwell, Brian M (2005) Molecular therapeutic targets in rheumatoid arthritis. Expert Reviews in Molecular Medicine, 7 (16). pp. 1-20. ISSN 1462-3994

Full text not available from this repository.


In an attempt to combat the pain and damage generated by rheumatoid arthritis (ra), new drugs are being developed to target molecular aspects of the disease process. Recently, a major development has been the use of biologicals (antibodies and soluble receptors) that neutralise the activity of tumour necrosis factor alpha (TNF-alpha) and interleukin 1 (IL-1), both of which are involved in disease progression. An increase in our understanding of cell and molecular biology has resulted in the identification and investigation of potential new targets, and also the refinement and improvement of current therapeutic modalities. This review describes therapies that are approved, in clinical trials or under pre-clinical investigation at the laboratory level, particularly focusing on cytokines, although other therapeutic targets of interest are mentioned.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: Q Science
R Medicine
Depositing User: Sandra Sacre
Date Deposited: 01 Nov 2012 11:44
Last Modified: 05 Oct 2017 18:27
📧 Request an update